Economic burden and health related quality of life of ultra-rare Gaucher disease in China

Xinye Qi1,2, Jiao Xu1,2, Linghan Shan1,2, Ye Li1,2, Yu Cui1,2, Huan Liu1,2, Lijun Gao1,2, Zheng Kang1,2 and Qunhong Wu1,2*

Abstract

Background: The diagnosis and health care of patients with rare diseases present a tremendous challenge worldwide. This study described the health care service utilization through participants’ perspective and estimated the cost of illness (COI), and patients with Gaucher disease (GD)’s/caregivers’ health-related quality of life in China.

Method: An online retrospective survey of patients with GD and their caregivers was conducted during May–June 2018. Socio-demographic, health service utilization, disease-related expenses, social support, sleep quality (Pittsburgh Sleep Quality Index [PSQI]), and the Short Form Health Survey (SF-36) were investigated. Using self-reported information, we estimated the annual COI, including direct healthcare, direct non-healthcare, and indirect costs.

Results: Forty patients and their 49 caregivers were surveyed. The patients’ onset age of GD was 9.3 ± 10.9; their disease course was 3.5 ± 3.1 years. 21 (42.9%) patients had ≥2 caregivers, but 35 (71.4%) caregivers reported have no experience as a caregiver. 79.6% caregivers have stopped working, and 87.8% changed weekly working schedule. Before final diagnosis, patients visited 3.9 ± 3.1 (max = 20) hospitals and took 1.2 ± 1.7 (max = 6.6) years for confirmed diagnosis. On average, 5.0 ± 9.6 misdiagnoses occurred, and the per-patient diagnoses cost was USD ($) 7576. After GD confirmation, 8 (16.3%) patients received no treatment, 40 (81.6%) received pharmacotherapy, 10 (20.4%) received surgery, 38 (77.6%) received outpatient service (8.8 ± 9.1 times/annually), and 37 (77.5%) received inpatient service (4.0 ± 3.5 times/annually). Annual per-patient COI was USD ($) 49,925 (95% confidence interval: 29,178, 70,672). Average direct healthcare cost was $41,816, including pharmaceutical ($29,908), inpatient ($7,451), and outpatient ($1,838). Productivity loss per-caregiver was $1,980, and their Zarit Burden Inventory score was moderate-severe (48.6 ± 19.6). Both patients/caregivers reported lower social support (32.4 ± 7.4, 34.9 ± 7.6), two times higher PSQI (7.9 ± 2.9, 8.7 ± 3.6), and half lower SF-36 (41.3 ± 18.6, 46.5 ± 19.3) than those reported for healthy Chinese individuals.

Conclusions: The high misdiagnosis rate, together with delayed diagnosis, substantial costs, and deteriorated health-related quality of life of GD patients as well as their heavy care burden, calls for extreme attention from policymakers in China. Further efforts of government and society are urgently demanded, including pharmaceutical reimbursement, screening newborns, developing precise diagnostic tools, and training doctors.

Keywords: Gaucher disease, Health service utilization, Cost of illness, Health status, Caregiver, Diagnoses

Background

Gaucher disease (GD), an ultra-rare multi-organ involvement, inherited recessive enzyme deficiency [1, 2], is slowly progressing. Its standardized incidence and prevalence among the general population worldwide vary from 0.30 to 5.80 per 100,000 population, respectively; however, the initial estimate was 0.25 to 1.24 per
100,000 population [3, 4] with hundreds of patients diagnosed with GD in China. Accompanying symptoms of GD include anemia, thrombocytopenia, splenomegaly, hepatomegaly, and bone involvement [5], which often cause significant impairments to their health and the quality of life. And once diagnosed, it ought to be managed with enzyme replacement therapy [6, 7], but results in enormous expenses.

Currently, the effective therapy for GD patients, such as enzyme replacement therapy and substrate reduction therapy, which must be administered continually, are extremely costly for patients and caregivers [8, 9]. Further, caregivers may experience workdays loss, absenteeism, and job changes while caring for their patients [10]. Measuring the economic cost of illness can provide better information to policymakers to develop more targeted interventions to GD at various levels of the health care system [11]. Measuring the economic and care burdens of diseases to the society will facilitate the prioritized healthcare policies and strategies [1]. However, evidence on the financial burden (e.g., direct healthcare costs, direct non-healthcare costs, and indirect costs) associated with GD in China is limited [12, 13]. Extensive health care utilization and frequent medical care and expenses are associated with the economic burden of patients and caregivers [14]. Hence, it is essential to identify costs and health-related quality of life of GD patients/caregivers in China [15].

The World Health Organization has emphasized the need for urgent action to diagnose and treat people with rare diseases [16]. However, the diagnosis and treatment of rare diseases in China are still at a preliminary stage. Definitive GD diagnosis in China is difficult, especially with the high phenotypic heterogeneity of GD [17]. Several studies have explored the length of time required for diagnosing rare diseases [18, 19]. A long duration is often required before a correct diagnosis or treatment, which implies considerable discomfort for the patients with rare diseases, such as GD, and their families. To the best of our knowledge, few studies have focused on health service utilization and costs of GD, including the diagnosis [20].

This study aimed to describe the health care service utilization through participants’ perspective, estimated the cost of illness, health-related quality of life of patients with GD, and the quality of life of their caregivers.

**Methods**

**Development of the survey**

An online retrospective survey of patients with GD and their caregivers was conducted for data collection. The inclusion criteria for patients were as follows: (i) a diagnosis of GD by a physician before the study; (ii) with a caregiver who was familiar with the whole treatment process of them; (iii) if the patient was under 15, with a voluntary caregiver to help answer all the real information of them. The inclusion criteria for the caregivers included that he/she was: (i) the primary caregiver; (ii) thoroughly familiar with the patient's disease; (iii) accompany patients every visit to the treatment; and (iv) was able to understand the content of the questionnaire.

The China Gaucher disease family exchange group (C-GDFEG) is currently the largest GD information exchange platform in China. The questionnaire, including the patient part and the caregiver part, was distributed simultaneously to eligible patients with GD and their caregivers. In the case of patients <15 years or patients who are dependent partly or on full-time care, the patient part asked whether the patient can answer independently, and questions were set up in two ways (et al., “Birthdate of you” or “Birthdate of the patient”). The patient part was answered by themselves or with their caregivers’ help if they can understand questions; if not, patients’ information will be answered only by their caregivers.

**Questionnaire design and data collection**

From the literature review, we identified key areas that were both important for the patients and families, and essential for the health authorities and service provision planning. The online self-administered questionnaire for the patients with GD, their caregivers, and their households comprised the following sections: (i) socio-demographic characteristics; (i) health service utilization; (ii) cost of illness; (iii) social support; (iv) sleep quality; (v) care burden; and (vi) self-reported health (using SF-36).

**Definition and measurements**

**Socio-demographic characteristics**

The patients’ socio-demographic characteristics included age, sex, current residence, mean age at onset, disease duration, type of GD, family history of GD, and caregivers’ number. Socio-demographic characteristics of the caregivers included the daily care time, experience of being a caregiver, stopped working because of patients’ GD, change of weekly working scheme because of patient’s GD, and members with chronic disease >60/<5 years of age. Besides, whether living on minimum subsistence allowance or relatives’ relief or not was also reported.

**Health service utilization and caregivers’ perception of GD treatment**

The health service utilization data were collected in this study to assess patients’ diagnosis and treatment status. Health service utilization covering the 12 months health service utilization of patients with GD surveyed
by self-designed questions, including the following: (i) the original reason to see the doctors; (ii) symptom; (iii) types of medical institutions frequently visited; (iv) the number of hospitals visited for GD diagnosis; (v) total cost of GD diagnosis; (vi) length before the final GD diagnosis was confirmed; (vii) misdiagnoses; (viii) the number of misdiagnoses; (ix) therapy after GD diagnosis; (x) outpatient/inpatient visit for GD; (xi) traffic time; and (xii) surgery/pharmacologic therapy after GD diagnosis.

Additionally, caregivers’ perceptions, “the availability and affordability of therapeutic drugs,” “difficulties during GD treatment,” “knowledge of GD,” and “difficulties to get diagnosis information” were also investigated.

Cost of illness
We retrospectively evaluated the total cost of GD, comprising direct healthcare, direct non-healthcare, and indirect costs for patients and their families. Costs comprised the following components: Direct healthcare costs: (i) daily outpatient/inpatient treatment cost; (ii) laboratory and diagnostic costs; (iii) imported/domestic drugs’ costs; (iv) formal care cost; (v) other direct outpatient/inpatient medical costs; Direct non-healthcare costs: (vi) outpatient/inpatient costs for accommodation/transportation/meals; (vii) artificial nutrition costs; (viii) other direct non-healthcare costs; and Indirect costs: (ix) daily lost wages of caregivers.

Respondents were also asked to recall the use of resources: (i) outpatient/inpatient visit frequencies (consultations) annually; (ii) the average days for each outpatient/inpatient visit; and (iii) total days of lost wages annually. The resources used were multiplied by the corresponding unit cost to estimate the annual cost per patient, and the monetary values of the unit prices were reported in USD [$, Purchasing Power Parities in the study years of OECD National Accounts Statistics (2018): https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm#indicator-chart.]

Zarit Burden Inventory
The subjective burden of the caregivers was measured by ZBI (22-item version), with item scores ranging from 0 (never) to 4 (nearly always). The total score ranges from 0 to 88, and scores <21 correspond to little or no burden while scores >61 correspond to severe burden [21].

Social Support Rating Scale
SSRS comprises 10 items and includes three subscales: subjective support (4 items), objective support (3 items), and utilization of support (3 items). The total SSRS score ranges from 12 to 66 points, and higher scores indicate a higher level of social support [22].

Pittsburgh Sleep Quality Index
Sleep quality of individuals in 1 month was measured using the PSQI (comprises 19 items and 7 dimensions), which includes subjective sleep quality, sleep onset latency, total sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The sub-total of the scores of each dimension ranges from 0 to 3, and the maximum score is 21. The cut-off score for PSQI-defined cases of poor sleep quality is ≥6. A Chinese PSQI version has been validated with adequate reliability [23].

The medical outcomes study 36-item Short Form
Quality of life was measured by the SF-36 comprising 36 items, including the physical and mental component scores [24]. Subscale scores are then transformed from the normal scale to a 0–100 standardized score scale, with higher scores indicating more positive health status and a better health-related quality of life.

Statistical analyses
Descriptive analysis was conducted to evaluate the socio-demographic characteristics, the status of health service utilization, cost of illness, and health-related quality of life. Continuous variables were presented as means ± SDs, and categorical variables were presented as absolute and relative frequencies. The 2.5 and 97.5% quantiles of the bootstrap distribution were used as the limits of the 95% CI. Subgroup comparisons of health-related quality of life and COI were conducted using student t-tests for two groups and one-way ANOVA tests for three or more groups. Correlation analysis were used to continuous variables. All statistical analyses were conducted using SAS software, version 9.4 (SAS Institute, North Carolina, US).

Results
Socio-Demographic characteristics
From May to June 2018, we contacted a total of 98 families of patients with GD in C-GDFEG before conducting this survey. A total of eligible 51 (52.04%) patients enrolled in this study. Both the patient part and the caregiver part completely answered was considered as a valid questionnaire. Of them, 49 (validity rate 96.08%) patients with GD and their caregivers (n = 49) completed the questionnaire were included in this study. The contact details of the researchers were also sent to the participants for information and further communication.

Characteristics of enrolled patients with GD, families, and caregivers are shown in Table 1, which shown GD often occur in child and adolescents.
Among patients’ families (see in Additional file 1: Table 1), 18.4% had a family history of GD, and 85.7% had family members aged > 60 years. We have measured the daily care time of care by a closed-form problem with four options (1 = < 6 h, 2 = 6–12 h, 3 = 12–18 h, 4 = 18–24 h); therefore, we are unable to provide the mean daily care time of care. Among the 49 caregivers, 81.6% reported caring for the patients for > 6 h daily, and 71.4% having no caregiving experience. Furthermore, 79.6% and 87.8% of caregivers stopped working and absenteeism. The Zarit Burden Inventory (ZBI) score, indicating the burden of the caregivers, was from moderate to severe (48.57 ± 19.57).

### Table 1 Characteristics of enrolled patients with Gaucher disease

| Items                                      | Sample (n) | Proportion (%) |
|--------------------------------------------|------------|----------------|
| **Sex**                                    |            |                |
| Male                                       | 25         | 51.0           |
| Female                                     | 24         | 49.0           |
| **Age group (mean age at survey) in years**|            |                |
| 0–4                                        | 19         | 38.9           |
| 5–7                                        | 5          | 10.2           |
| 8–12                                       | 12         | 24.5           |
| 13–14                                      | 2          | 4.1            |
| ≥ 15                                       | 11         | 22.5           |
| **Age at onset, years**                    |            |                |
| Mean ± SD                                  | 9.3 ± 10.69|                |
| Max                                        | 44         |                |
| Min                                        | 1          |                |
| **Disease course from symptom onset, days**|            |                |
| Mean ± SD                                  | 3.5 ± 3.1  |                |
| Max                                        | 12.1       |                |
| Min                                        | 0.3        |                |
| Median                                     | 2.0        |                |
| **Types of Gaucher disease (GD)**          |            |                |
| Type I                                     | 20         | 40.8           |
| Type II                                    | 5          | 10.2           |
| Type III                                   | 4          | 8.2            |
| Not clear                                  | 20         | 40.8           |
| **Number of caregivers**                   |            |                |
| 1                                          | 28         | 57.1           |
| ≥ 2                                        | 21         | 42.9           |

SD standard deviation

Among patients’ families (see in Additional file 1: Table 1), 18.4% had a family history of GD, and 85.7% had family members aged > 60 years. We have measured the daily care time of care by a closed-form problem with four options (1 = < 6 h, 2 = 6–12 h, 3 = 12–18 h, 4 = 18–24 h); therefore, we are unable to provide the mean daily care time of care. Among the 49 caregivers, 81.6% reported caring for the patients for > 6 h daily, and 71.4% having no caregiving experience. Further, 79.6% and 87.8% of caregivers stopped working and absenteeism. 79.6% changed their weekly working schedule. The Zarit Burden Inventory (ZBI) score, indicating the burden of the caregivers, was from moderate to severe (48.57 ± 19.57).

### Health service utilization

The profile of health service utilization of patients with GD is shown in Additional file 1: Table 2. Patients’ original reasons for visiting the doctors included enlarged liver and spleen (71.4%), normocytic anemia (36.7%), dyskinesia (12.2%), and osteopenia (8.2%). Among all surveyed patients, the two most frequent symptoms were hepatosplenomegaly (85.7%) and normocytic anemia (73.5%). Many patients (43.5%) reported that they had to travel to the tertiary hospitals in other provinces to get confirmed diagnosed. Among 49 patients, 77.6% received outpatient service, and 77.5% received inpatient service.

Hardly recognized by many doctors, the patients visited 3.9 ± 3.1 hospitals, and it took 1.2 ± 1.7 (median = 0.4, max = 6.6) years for the diagnosis to be confirmed. The total cost for GD diagnosis was USD ($) 7575.8 (median); 59.2% of patients experienced ≥ 1 misdiagnosis, with a mean of 5.0 (SD = 9.6, median = 2.0). Before the correct diagnosis, most patients were misdiagnosed with unexplained splenomegaly (65.5%), hypersplenism (44.8%), and hemophilia (10.2%). Eight (16.3%) patients received no health service following GD diagnosis. Ten patients underwent surgery (20.4%; splenectomy = 9; hematopoietic stem cell transplantation = 1). The remaining 40 (81.6%) received pharmacotherapy, among whom 14 (35.0%) had not used medications as prescribed, 27 (67.5%) reported using imported drugs, 9 took imiglucerase (the medicine used treatment of GD), and 5 were still using imiglucerase from the onset of GD diagnosis; all 49 (100%) agreed that the high price of medicine led to the failure of compliance with the doctor’s prescription. Furthermore, 36 (90.0%) reported purchasing their medications at medical institutions or pharmacies, while 31 (71.5%) purchase from overseas.

Additional file 1: Table 1 shows the caregivers’ perception of GD treatment. Most (89.8%) caregivers perceived that the availability of therapeutic drugs was problematic. All (100%) caregivers reported their inability to afford therapeutic drugs. 48 (98.0%) Caregivers reported having no knowledge of GD. Most (96.0%) caregivers felt difficulty in obtaining diagnosis information. The top two problems confronting the caregivers during GD treatment were “high treatment cost” (95.8%) and “far away from hospitals” (75.0%). Up to 79.6% of 49 caregivers were extremely unconfident about future treatment.

### Cost of illness

The cost of illness of patients with GD is shown in Table 2. In total, the mean annual economic burden of GD was estimated at $48,771. The mean direct healthcare costs of GD estimated at $41,816.2 (85.7% of total costs) mainly comprised of taking medicine at home (61.3% of total costs), inpatient treatment (15.3%), outpatient treatment (3.8%), and medical tests (3.4%).

The average annual direct non-healthcare costs added up to $4,974.4 (10.2% of total costs). With both direct healthcare and non-healthcare costs, the annual direct cost was estimated at $46,790.6. The indirect costs for
GD primarily originated from the productivity loss to the caregivers while caring for patients with GD (4.1% of total costs).

**Social support and health-related quality of life of patients and their caregivers**

The total Social Support Rating Scale (SSRS), Pittsburgh Sleep Quality Index (PSQI), and Short Form Health Survey (SF-36) scores for patients with GD, their caregivers, and norms of healthy Chinese people are shown in Table 3. Patients with GD and their caregivers reported mean SSRS scores of 25.3 ± 5.7 and 26.1 ± 5.6, respectively. Both were remarkably lower than the SSRS score (40.5 ± 6.8) for healthy Chinese people (all p-value < 0.05). The mean PSQI scores for patients and caregivers scores were 7.9 ± 2.9 and 8.7 ± 3.6, respectively. Patients with GD and their caregivers reported two times higher PSQI scores than the normal values for healthy Chinese people (3.9 ± 2.5) (all p-value < 0.05). Overall, 16 (32.7%) of caregivers rated sleep problems using PSQI dimensions. All the seven PSQI dimension scores for the caregivers were higher than the normal values for healthy Chinese people (all p-value < 0.05).

Besides, the health-related quality of life of the patients with GD and caregivers was assessed. Patients (39.4 ± 22.4) and caregivers (47.6 ± 23.0) reported a half lower Physical Component Summary than the normal values for healthy Chinese people (77.5 ± 16.0, all p-value < 0.05). Further, Mental Component Summary in both patients (43.2 ± 16.1) and caregivers (45.4 ± 20.4) was significantly half lower than the normal values in healthy Chinese people (71.3 ± 17.9, all p-value < 0.05).

The COI of GD patients with splenectomy surgery is significantly different with GD patients without (F = 4.634, P = 0.017), and GD patients taking medication in Table 2

|                     | Mean annual costs | 95% CI     | Ratio of COI (%) |
|---------------------|-------------------|------------|-----------------|
|                     | Low limit         | Upper limit|                 |
| Direct healthcare   | 41,816.2 ± 65,745.4 | 21,064.4  | 62,568.0       | 85.74 |
| Outpatient medical  | 1838.1 ± 3029.4    | 881.9      | 2794.4         | 3.77  |
| Inpatient medical   | 7451.2 ± 10,392.2  | 4171.1     | 10,731.4       | 15.28 |
| Pharmaceutical      | 29,907.6 ± 63,861.1| 9750.6     | 50,064.7       | 61.32 |
| Medical tests       | 1675.9 ± 3207.2    | 663.6      | 2688.2         | 3.44  |
| Formal care         | 580.6 ± 817.7      | 322.5      | 838.7          | 1.19  |
| Other cost/expenses | 362.7 ± 654.3      | 156.2      | 569.3          | 0.74  |
| Other cost/expenses | 88.1 ± 159.7       | 37.7       | 138.5          | 0.18  |
| Other cost/expenses | 274.6 ± 633.0      | 74.8       | 474.5          | 0.56  |
| Direct non-healthcare| 4974.4 ± 4675.9    | 3498.5     | 6450.3         | 10.20 |
| Accommodation       | 1245.0 ± 1711.2    | 704.9      | 1785.1         | 2.55  |
| Accommodation of outpatient | 440.3 ± 597.8 | 251.6 | 629.0          | 0.90  |
| Accommodation of inpatient | 804.7 ± 1562.6 | 311.5 | 1297.9         | 1.65  |
| Transportation      | 819.9 ± 841.5      | 365.3      | 1208.5         | 1.68  |
| Transportation of outpatient | 581.8 ± 685.9 | 239.0 | 706.2          | 0.97  |
| Transportation of inpatient | 238.0 ± 376.3 | 119.3 | 356.8          | 0.49  |
| Meals               | 749.8 ± 874.9      | 373.7      | 1026.0         | 1.54  |
| Meals of outpatient | 277.3 ± 356.2      | 164.8      | 389.7          | 0.57  |
| Meals of inpatient  | 472.6 ± 740.1      | 239.0      | 706.2          | 0.97  |
| Costs for artificial nutrition | 1340.0 ± 2796.6 | 457.3 | 2222.7         | 2.75  |
| Other cost/expenses | 819.7 ± 929.0      | 526.4      | 1129.9         | 1.68  |
| Direct cost         | 46,790.6 ± 65,714.2| 26,048.6  | 67,532.5       | 95.94 |
| Indirect cost       | 1980.4 ± 1962.8    | 1360.9     | 2600.0         | 4.06  |
| Cost of illness (COI)| 48,771.0 ± 65,616.8| 28,059.8 | 69,482.2       | 100.00 |

Because of rounding, percentage might not add up to exactly 100%

COI = cost of illness; COI is the annual per-patient in this study

The medical costs were converted to US Dollar using Purchasing Power Parities (PPP) in the study years (2018) (OECD National Accounts Statistics: PPP https://data.oecd.org/conversion/purchasing-power-parities-ppp.html#indicator-chart)
as prescribed is significantly different with GD patients without \((F = 6.454, P = 0.003)\). Duration of GD final confirmed diagnosis \((r = 0.458, p = 0.003)\) and the difficulty to get diagnose \((r = 0.388, p = 0.012)\) are positively relative to the COI of GD patients (Additional file 1: Table 4).

The quality of life of GD patients with bone pain or other bone symptoms is significantly different with non-bone symptoms \((F = 4.984, p = 0.053)\). The health condition of GD patients \((r = 0.760, p = 0.007)\) is positive relative to the quality of life of GD patients (Additional file 1: Table 5).

The quality of life of caregivers caring for patients with different types of GD is significantly different \((F = 3.528, P = 0.022)\). Patients with nervous system involvement symptoms are significantly different with non \((F = 2.675, P = 0.001)\). Economic pressure \((r = -0.438, p = 0.002)\)

### Table 3 Psychosocial burden of Gaucher disease on the caregivers

| SSRS\(^c\)               | Patients (n = 30) | Caregivers (n = 49) | Norm of healthy Chinese | P\(^a\) | p\(^b\) |
|--------------------------|-------------------|---------------------|-------------------------|--------|--------|
| Maximum score, 40 points |                    |                     |                         |        |        |
| Objective support        | 8.2 ± 2.5         | 8.2 ± 2.3           | 9.1 ± 2.9               | 0.059  | 0.009  |
| Subjective support       | 17.6 ± 5.0        | 19.9 ± 4.9          | 23.5 ± 4.3              | < 0.001| < 0.001|
| Utilization of support   | 6.6 ± 1.8         | 6.7 ± 1.9           | 7.8 ± 2.0               | 0.001  | < 0.001|
| Mean ± SD                | 32.4 ± 7.4        | 34.9 ± 7.6          | 40.5 ± 6.8              | < 0.001| < 0.001|

### PSQI\(^d\)

| Maximum score, 21 points | Patients (n = 30) | Caregivers (n = 49) | Norm of healthy Chinese | P\(^a\) | p\(^b\) |
|--------------------------|-------------------|---------------------|-------------------------|--------|--------|
| Not good                 | 6 (20.0)          | 16 (32.7)           |                         |        |        |
| Good                     | 24 (80.0)         | 33 (67.3)           |                         |        |        |
| Mean ± SD                | 7.9 ± 2.9         | 8.7 ± 3.6           | 3.9 ± 2.5               | < 0.001| < 0.001|
| Subjective sleep quality | 1.57 ± 0.97       | 1.71 ± 0.89         | 0.63 ± 0.68             | < 0.001| < 0.001|
| Sleep latency            | 1.77 ± 0.77       | 1.59 ± 0.91         | 0.70 ± 0.86             | < 0.001| < 0.001|
| Sleep duration           | 0.87 ± 1.01       | 1.24 ± 0.97         | 0.70 ± 0.58             | < 0.001| < 0.001|
| Habitual sleep efficiency| 0.27 ± 0.69       | 0.63 ± 0.86         | 0.15 ± 0.47             | < 0.001| < 0.001|
| Step disturbance          | 1.73 ± 0.52       | 1.61 ± 0.57         | 0.90 ± 0.44             | < 0.001| < 0.001|
| Use of sleeping medication| 0.00              | 0.08 ± 0.34         | 0.06 ± 0.24             | –      | < 0.001|
| Daytime dysfunction       | 1.67 ± 1.03       | 1.82 ± 1.11         | 0.73 ± 0.83             | < 0.001| < 0.001|

### SF-36\(^e, f\)

| Maximum score, 100 points for each item | Patients (n = 30) | Caregivers (n = 49) | Norm of healthy Chinese | P\(^a\) | p\(^b\) |
|----------------------------------------|-------------------|---------------------|-------------------------|--------|--------|
| Total score                            | 41.3 ± 18.6       | 46.5 ± 19.3         |                         |        |        |
| Physical Component Summary (PCS)       | 39.4 ± 22.4       | 47.6 ± 23.0         | 77.5 ± 16.0             | < 0.001| < 0.001|
| Mental Component Summary (MCS)         | 43.2 ± 16.1       | 45.4 ± 20.4         | 71.3 ± 17.9             | < 0.001| < 0.001|
| Physical functioning (PF)              | 63.2 ± 20.2       | 63.8 ± 30.2         | 87.9 ± 17.0             | < 0.001| < 0.001|
| Role physical (RP)                     | 13.6 ± 32.3       | 27.6 ± 43.1         | 77.5 ± 34.9             | < 0.001| < 0.001|
| Bodily pain (BP)                       | 51.8 ± 23.3       | 60.3 ± 26.3         | 82.2 ± 17.0             | < 0.001| < 0.001|
| General health (GH)                    | 29.0 ± 25.9       | 38.9 ± 21.9         | 62.5 ± 17.9             | < 0.001| < 0.001|
| Vitality (VT)                          | 42.7 ± 16.5       | 45.3 ± 18.6         | 68.2 ± 17.6             | < 0.001| < 0.001|
| Social functioning (SF)                | 71.6 ± 26.9       | 67.6 ± 30.0         | 80.7 ± 20.0             | 0.013  | 0.004  |
| Role emotional (RE)                    | 6.1 ± 20.1        | 20.4 ± 37.2         | 67.9 ± 39.4             | < 0.001| < 0.001|
| Mental health (MH)                     | 52.4 ± 17.1       | 48.3 ± 16.0         | 68.5 ± 16.9             | < 0.001| < 0.001|

SSRS = Social Support Rating Scale; PSQI = Pittsburgh Sleep Quality Index; SF-36 = Medical Outcomes Study 36-item Short Form; SD = standard deviation

\(^a\) Patients vs. normal values for healthy Chinese

\(^b\) Caregivers vs. normal values for healthy Chinese

\(^c\) N = 3342 [72]

\(^d\) N = 112 [73]

\(^e\) N = 17,754 [74]

\(^f\) N of patients ≥15 is 11
and difficulty in caring for GD patients ($r = -0.490, p < 0.001$) are negatively correlated with caregivers’ health-related quality of life. Health condition of GD patients ($r = 0.465, p = 0.001$) and the objective support received by GD caregivers ($r = 0.320, p = 0.025$) are positively related to the quality of life of GD caregivers (Additional file 1: Table 6).

**Discussion**

There is a dearth of evidence on the health service utilization and economic burden of rare disease patients with GD in China. In this study, we identified problems of patients with GD in their health service utilization, cost of illness, and health-related quality of life associated with GD in China. Families of patients with GD often experienced delays in diagnosis and misdiagnosis, enormous economic cost, and caregiving burden. Lack of social support often resulted in deteriorated health related quality of life and other major health issues which deserve great attention of society.

Misdiagnosis or delayed diagnosis is especially detrimental to patients [25]. Although several publications have acknowledged that diagnostic delays or misdiagnosis often occurs in obtaining a definitive GD diagnosis [26], this study further quantified the exact time delay and difficulty in obtaining the correct diagnosis that occurred in 79.6% surveyed patients. Studies indicated the process of continually seeking diagnosis was a traumatic experience for patients with rare diseases [27]. Davari M et al. have shown a patient misdiagnosed with GD had taken medications for ten years at the cost of $207,580 [1]. Thus, a rapid precise diagnosis of patients is essential for reducing unnecessary tests or costs [26, 28, 29], and preventing psychological stress for the family [30].

The main reason for the prolonged diagnostic delay most likely is insufficient knowledge on GD [31–33] by the medical community due to its low prevalence, extreme variations in clinical manifestations [28, 34], and severity of symptoms (e.g., bone pain/bone crisis, thrombocytopenia, and splenomegaly) [20, 26, 28]. Nevertheless, a survey revealed that only one of five hematologist–oncologist considers GD in the differential diagnosis of patients with a history of anemia, thrombocytopenia, hepatomegaly, splenomegaly, and bone pain. In this study, 79.6% of patients had visited doctors with obvious symptoms (osteopenia, normocytic anemia, dyskinesia, and obviously enlarged liver) in whom GD was not diagnosed in a timely manner. Therefore, establishing an information center of rare disease symptoms [35] and providing training on diagnostic methods and appropriate clinical guidelines to medical doctors are essential to effectively support the early diagnosis of rare diseases.

Besides, because most rare diseases are caused by DNA mutations or are recessive genetic diseases [36], family history and genetic screening could facilitate earlier diagnosis, while genetic testing can be used to confirm disease diagnosis [37]. Nine families reported a family history of the same disorder in this study, indicating a need for awareness of genetic disorders to highlight the importance and burden of genetic diseases. Therefore, newborn screening for disorders that meet the criteria for population screening [38], use of reliable diagnostic tools [1, 39–41], raising of awareness on the early signs/symptoms [42] or less severe manifestation [26], and initiation of therapy early for rare diseases [35], are essential.

In particular, long-term treatment with regular monitoring for GD can optimize outcomes [43], alleviate fewer exacerbations [1], and reduce the incidence of complications [44]. A Gaucher outcome survey involved 1209 patients with GD reported the overall treatment (1209, 73.4%) and different treatment rates in countries [the UK (119, 93.3%), Israel (536, 63.6%), the US (380, 82.6%), rest of the world (174, 69.5%)] [45]. In this study, 8 of the 49 patients (16.3%) were never treated, while 83.7% get treated, and 10 (20.4%) of patients undergone splenectomy, which was higher than previous research (8.7–13.3%) [2, 45]. Besides, other studies have also shown a significant proportion of patients (e.g., asymptomatic or mildly affected) never accessed medical attention or required treatment [46, 47]. In this study, even 20 (40.8%) of patients did not clear the type of their GD. Maaswinkel Mooij et al. [48] found that no treatment for type 1 GD with enzyme replacement therapy can worsen the condition at any age in non-Jewish patients [49]. Besides, 4 of 9 patients who took imiglucerase interrupted their treatment in this study. However, Drellichman et al. emphasized the need to avoid interruption of medical treatment of patients with GD because of recurrent organomegaly, growth delays, and skeletal manifestations [50]. Furthermore, a previous study identified the association of high immunoglobulin (Ig) A and IgG levels with long-term complications [51]. Therefore, long-term treatment and surveillance are required for improving the efficiency of GD management [52].

To estimate the annual cost of GD, we presented the core components of costs for health care services separately, from the payer’s perspectives, excluding patients’ out-of-pocket costs. The estimated annual per-patient cost of GD of $48,771 (95% confidence interval [CI]: $28,060, $69,482, which is 5.2 times of GDP per capita of China in 2018($9,377) [53]. The additional time spent by caregivers for providing care reflects an annual productivity loss of $1,980 per patient. In contrast, a recent analysis using the human capital approach (economic evaluation) showed high costs [e.g., Splenectomy
Currently pay out-of-pocket for international treatments. A low availability of < 30% [13], many Chinese patients included GD on the first list of rare diseases [60]. With the earliest launch time globally, the average delay availability of orphan drugs in China [13, 59]. Compared to the market authorization of orphan drugs for rare diseases in China was 7.7–9 years [13, 59]. Imiglucerase received China’s marketing authorization in 2008 [13]. On May 22, 2018, the Chinese Government officially included GD on the first list of rare diseases [60]. With a low availability of < 30% [13], many Chinese patients currently pay out-of-pocket for international treatments that are currently unapproved in China [61]. Second, lack of research and development and supply incentive policies for orphan drugs are possible reasons leading to low market availability [61]. Under a market-oriented economy, due to a small market share of orphan drugs, most pharmaceutical manufacturers are unwilling to invest in research and development on the production of orphan drugs without an incentive policy [13]. Third, public availability of orphan drugs is another major issue both for the patients [62] and the Chinese government. In this study, 31 (77.5%) of patients reported purchasing medicine at pharmacies or overseas. Due to the unique market attributes (e.g., low market volume, low profit, low turnover rate, and high price) of orphan drugs, and as the reform of public hospitals in China stipulated (control the share of drug sales in total hospital revenue), hospitals have little incentive to stock and prescribe expensive orphan drugs [63]. Lastly, there are no public national or provincial networks for rare diseases or orphan drugs to share useful information about these diseases, e.g., treatment or supply information. Therefore, it is urgent to improve the availability of rare drugs, e.g., simplify the approval procedure for imported orphan drugs, increase research and development investment, formulate incentive policies, and establish information-sharing platforms.

Furthermore, to recoup research and development costs and for profit, orphan drug manufacturers often adopt a strategy of charging high prices [64]. Miglustat and imiglucerase, which are effective medications for treating GD, had annual costs of $116,800 and $140,200, respectively in 2004 [65], and the expenditure was >3% of per capita GDP [12]. A study focusing on seven selected rare diseases found that the affordability of treatment was relatively poor, with the health expenditure for GD equivalent to 69.34 years per urban resident’s income in 2014 [12]. In this study, all patients reported the unaffordability of therapeutic drugs. The COI of GD patients taking medication as prescribed ($68,759.5 ± $75,457.7) is higher than GD patients without ($17,277.7 ± $19,382.4). High prices discourage patients from taking their medicine as prescribed. But considering the benefits of prescribed medication for patient control, clinicians should encourage patients to take medication as directed. A few cities/provinces are active in creating rare disease lists with a high reimbursement at 80–95% [66]. However, due to the restrictive reimbursement caps, even with 5% out-of-pocket expenses, few drugs could be afforded by high-income urban residents [67]. The out-of-pocket costs are still unaffordable for many patients. Therefore, the low affordability of orphan drugs may be closely associated with many factors, e.g., high drug prices, lack of insurance...
coverage, low reimbursement rates, and low-income levels for Chinese residents [13]. Several measures should be taken to improve the affordability of orphan drugs in China, including (1) formulating and implementing incentive policies [64, 68] to promote the development and supply of generic drugs, and to control the price of orphan drugs [69, 70]; (2) developing an orphan drug reimbursement system to increase insurance coverage; and (3) developing government-supported programs for patients with rare disease.

Due to the delayed diagnosis, unavailability, and unaffordability of costly drugs, 79.6% of 49 patients with GD felt poorly confident about future treatment. Moreover, the total social support, sleep quality, and quality of life scores for patients with GD/caregivers were significantly lower than those for normal healthy Chinese people. In this study, the health-related quality of life of GD patients with bone pain or other bone symptoms (31.58±5.54) is significantly lower than patients who have non-bone pain symptoms (52.95±22.72). Caregivers of type 1 GD patients have the highest health-related quality of life (51.29±20.31), followed by caregivers of type 3 GD patients (40.01±16.65) and caregivers of type 2 GD patients have the worst quality of life (23.38±11.62). The health-related quality of life of caregivers of GD patients with nervous system involvement symptom (29.29±11.52) is significantly lower than caregivers of non-neural system involvement GD patients (50.95±18.49). Clinicians should pay more attention to GD patients accompanied by skeletal symptoms and nervous system involvement. Meanwhile, the more objective support caregivers received, the higher the health-related quality of life of GD caregivers. Due to the nervous system involvement of type 2 GD [2], it is challenging to take care of patients with type 2 Gaucher’s disease. Health decision-makers and clinicians should take action to recover the life function of type 2 GD patients and give nursing suggestions to the caregivers of patients with Gaucher’s disease. The COI of GD patients with splenectomy surgery ($23,016.1±$16,832.3) is lower than GD patients without ($58,604.9±$73,187.1). The longer duration of the GD final confirmed diagnosis and the more challenging diagnosis, the higher COI of GD patients. Thus, the efficiency of clinical diagnosis should be improved. Simultaneously, clinicians need to judge the patient’s condition accurately, and surgery is recommended if the indications are met. Therefore, patients with GD experience substantial costs and low health-related quality of life [71]; clinicians and society should help patients with Gaucher’s disease and their families as early as possible.

Limitations
First, this study is limited primarily by the small sample size. Due to the rarity of GD, data collection was challenging. Second, families who voluntarily participate in the GD patient registry may represent a more compliant and motivated patient cohort in general. Thus, the findings may not be generalized to all. Thirdly, this study relied on responders’ recall of health service utilization and the unit costs to capture a more inclusive set of cost components usually not included in billing data, such as traffic costs, formal care costs, and productivity loss to caregivers. To enhance the accuracy of the estimates reported, patients with GD and caregivers were asked to complete questions regarding the average consumption amount and costs per resource in the past year. However, recall bias may have led to errors. Fourthly, utilization and corresponding costs from pharmaceutical use of prescription were not included in the survey. For pharmaceutical costs, we asked for the “annual purchase of imported/domestic medicines,” which could have resulted in an underestimation of this study’s GD’s financial burden. Hence, appraisal costs using data from health insurance is needed. Lastly, it was no possible to estimate informal care costs due to the form of the question we design to request this information, but we assessed the productivity losses of informal caregivers.

Conclusions
Patients with GD often encountered the frustrating experience of high misdiagnosis rate, long-delayed diagnosis, substantial costs, and deteriorated health-related quality of life in China. For patients with GD, a rapid, precise diagnostic tool for earlier and timely definitive diagnosis of GD is urgently needed. Measures targeting improving the availability and affordability of orphan drug needs to be developed holistically in China. Furthermore, newborn screening for disorders that meet the criteria for population screening with reliable diagnostic tools should be explored. Besides, enhancing doctors’ ability in GD diagnosis and differential diagnosis, raising awareness of the early signs/symptoms or less severe manifestation to achieve earlier diagnosis and timely therapy of rare diseases, relieve caregivers’ burden, and provide much needed social support are essential. This research can facilitate greater societal awareness of rare diseases, help policymakers develop appropriate intervention programs, and inform healthcare-focused support schemes and policies for patients and their families.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-01963-6.

Additional file 1. Description/comparison of the characteristics, utilization of health service, perception of treatment, cost of illness, and scores of health-related quality of Gaucher disease (GD) families/caregivers/patients.

Acknowledgements

We wish to thank the patients and their families for participating in this study.

Authors’ contributions

Writing—original draft by XQ; Conceptualization and Methodology by XQ and JX; Resource by JX and QW; Writing—Review and editing by LS and YL; Writing—original draft by XQ; Conceptualization and Methodology by XQ.

Funding

The National Social Science Foundation of China (No.19AZD013).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Harbin Medical University (No.HMJURB20200001).

Consent for publication

Yes.

Competing Interests

The authors declare that they have no competing interests.

Author details

1. Department of Health Policy, Health Management College, Harbin Medical University, No. 157, Baqian 21 Road, Nangang District, Harbin 150081, Heilongjiang Province, China. 2. Department of Social Medicine, School of Public Health, Harbin Medical University, Harbin, Heilongjiang, China.

References

1. Davari M, Nabizadeh A, Kadivar M, Asl AA, Sarkheil P. Healthcare resource utilization and cost of care for Gaucher patients in Iran. J Diabetes Metab Disord. 2019;18:127–32.
2. Serratrice C, Stirnemann J, Berrahal A, Belmatoug N, Camou F, Caillaud C, et al. A cross-sectional retrospective study of non-splenectomized and never-treated patients with type 1 gaucher disease. J Clin Med. 2020;9:2343.
3. He J, Tang M, Zhang X, Chen D, Kang Q, Yang Y, et al. Incidence and prevalence of 121 rare diseases in China: current status and challenges. Intractable Rare Dis Res. 2019;8:889–97.
4. Yang Y, He J, Wang Y, Kang Q, Hu S. Study Feasibility of Multi-payment for Drugs for Rare Diseases—Taking Gaucher’s Disease in Qingdao as Example. China Pharm. 30:2593–6.
5. General Office. National Health Commission. Notice on publication of the Rare Diseases Diagnosis and Treatment Guide (2019) [Internet] [cited 2020 Nov 19]. Available from: http://www.nhc.gov.cn/yzjgj/s7659/ 201902/61d06b491634b8e01801ce1fbeb84433.shtml
6. Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med. 2008;132:851–3.
7. Cox TM, Drellichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Elyglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385:2555–62.
8. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018;13:107–18.
9. Dinur T, Isaiti M, Frydman D, Becker-Cohen M, Szer J, Zimman A, et al. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. Orphanet J Rare Dis. 2020;15:284.
10. Lyssczarz B. Indirect costs and incidence of caregivers’ short-term absenteeism in Poland, 2006–2016. BMC Public Health. 2019;19:598.
11. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37.
12. Xin X-Y, Guan X-D, Shi L-W. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China. Orphanet J Rare Dis. 2016;11:74.
13. Gong S, Wang Y, Pan X, Zhang L, Huang R, Chen X, et al. The availability and affordability of orphan drugs for rare diseases in China. Orphanet J Rare Dis. 2016;11:120.
14. Nalysnyk L, Hamed A, Hurwitz G, Simeone J, Rotella P. A Comprehensive literature review of the burden of Gaucher disease. Value Health. 2014;17:A391.
15. Hsu JC, Wu H-C, Feng W-C, Chou C-H, Lai EC-C, Lu CY. Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan’s National Health Insurance Research Database. PLoS ONE. 2018;13:e0204206.
16. Statement for Rare Disease Day [Internet]. [cited 2020 Nov 28]. https:// www.who.int/news/item/27-02-2018-statement-for-rare-disease-day
17. He J, Song P, Kang Q, Zhang X, Hu J, Yang Y, et al. Overview on social security system of rare diseases in China. Biosci Trends. 2019;13:314–23.
18. Evans WR. Dare to think rare: diagnostic delay and rare diseases. Br J Gen Pract. 2018;68:224–5.
19. Nalysnyk L, Hamed A, Hurwitz G, Simeone J, Rotella P. A Comprehensive literature review of the burden of Gaucher disease. Value Health. 2014;17:A391.
20. Motta I, Filocamo M, Poggiali E, Stroppiano M, Dragani A, Consolini D, et al. A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. Eur J Haematol. 2016;96:352–9.
21. Tang B, Harary E, Kurzman R, Mould-Quevedo JF, Pan S, Yang J, et al. Clinical characterization and the caregiver burden of dementia in China. Value Health Reg Issues. 2013;2:118–26.
22. Sun J, Sun R, Jiang Y, Chen X, Li Z, Ma Z, et al. The relationship between psychological health and social support: evidence from physicians in China. PLoS ONE. 2020;15:e0228152.
23. Wang X, Wang X, Ma H. Manual of Mental Health Rating Scale (Updated Edition) [Internet]. Beijing: Chinese Journal of Mental Health; 1999 [cited 2020 Nov 20]. https://www.hanspub.org/reference/ReferencePapers. aspx?ReferenceID=87567
24. Li L, Wang HM, Shen Y. Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health. 2003;57:259–63.
25. Pierre-Étienne C, Anne-Sophie C, Ségalène A, Christian D. Diagnostic delay in rare diseases: a documented list of (296) rare diseases for which delayed diagnosis would be especially detrimental, based on the French situation. 2020 [cited 2020 Nov 27]. https://www.researchsquare.com/ article/rs-32308/v1
26. Andrade-Campos M, Alfonso P, Irún P, Armstrong J, Calvo C, Dalmajr J, et al. Diagnosis features of pediatric Gaucher disease patients in the era
of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease. Orphanet J Rare Dis. 2017;12:84.

27. Experiences of Rare Diseases: An Insight from Patients and Families (2010) [Internet]. Rare Disease UK. 2010 Dec. p. 37. Available from: https://www.raredisease.org.uk/our-work/experiences-of-rare-diseases-an-insight-from-patients-and-families-2010/

28. Thomas AS, Mehta AB, Hughes DA. Gauging Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells Mol Dis. 2013;50:212–7.

29. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists – oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82:697–701.

30. Anderson M, Elliott EJ, Zunyrski YA. Australian families living with rare disease: experiences of diagnosis, health service use and needs for psychosocial support. Orphanet J Rare Dis. 2013;8:22.

31. Chopra M, Duan T. Rare genetic disease in China: a call to improve clinical services. Orphanet J Rare Dis. 2015;10:140.

32. Xuefeng L, Xiangyu Z, Shu Z, Zijuan L, Jianyong Z, Jincheng Z, et al. Rare diseases in China. J Chin Pharm. 2018;27:361–9.

33. Chopra M, Duan T. Rare genetic disease in China: a call to improve clinical services. Orphanet J Rare Dis. 2015;10:140.

34. Mengyuan F, Xiaodong G, Guoxu W, Xiaoxiong X, Luwen S. Medical service utilisation, economic burden and health status of patients with rare diseases in China. J Chin Pharmacol. 2018;28:361–9.

35. Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Informatics in rare disease: a questionnaire-based study in Belgium. Orphanet J Rare Dis. 2019;14:99.

36. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discovery. 2004;3:93–5.

37. Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Rare diseases and orphan drugs. Nat Rev Drug Discovery. 2004;3:93–5.

38. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists – oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82:697–701.

39. Huang Y, Jia X, Tang C, Liu S, Sheng H, Zhao X, et al. High risk screening for high-risk Gaucher disease children using dried blood spot methods in Shandong province of China. Orphanet J Rare Dis. 2018;13:48.

40. Lei K, Zhao Y, Sun L, Liang H, Luo R, Sun X, et al. A pilot screening of high-risk Gaucher disease children using dried blood spot methods in Shandong province of China. Orphanet J Rare Dis. 2018;13:48.

41. Mehta A, Belaymutou N, Bembí B, Debeer P, Elstein D, Güker-Alpan Ö, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;212:122–9.

42. Mehta A, Kuter DJ, Salek SS, Belaymutou N, Bembí B, Bright J, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. Intern Med. 2019;45:578–91.

43. Kaplan B, Baris H, De Meirick L, Di Rocco M, El-Beshlawy A, Huemer M, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013;172:447–58.

44. van Dussen L, Biegstraaten M, Dijkgraaf MG, Hollak CE. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis. 2014;9:112.

45. Zimran A, Belaymutou N, Bembí B, Debeer P, Elstein D, Fernandez-Sasso D, et al. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher Outcome Survey (GOS). Am J Hematol. 2018;93:205–12.

46. Dinur T, Zimran A, Becker-Cohen M, Arkadir D, Cozma C, Hovakimyan M, et al. Long term follow-up of 103 untreated adult patients with Type 1 Gaucher disease. J Clin Med. [Internet]. 2019:8. https://doi.org/10.3390/jcm8101662

47. Schländer M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin. 2009;25:1285–93.

48. Maaswinkel-Mooij P, Hollak C, van Eyssen-Plaisier M, Prins M, Aerts H, Poll R. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis. 2000;23:77–82.

49. Weinreb NJ, Barbouth DS, Lee RE. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. Blood Cells Mol Dis. 2018;68:211–7.

50. Drellichman G, Poncè E, Basak N, Feigreiro D, Aversa L, Graciela E, et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr. 2007;151:197–201.

51. Andrade-Campos MM, de Frutos LL, Cebolla JJ, Serrano-Gonzalo I, Medrano-Engay B, Roca-Espau M, et al. Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis. 2020;15:256.

52. Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Munjan M, et al. Diagnosis and Management of Gaucher Disease in India—consensus guidelines of the Gaucher disease task force of the Society for the Indian Academy of Pediatrics and the Indian Academy of Genetics and the Indian Academy of Pediatrics. Indian Pediatr. 2018;55:11.

53. National Data [Internet]. [cited 2020 Nov 17]. Available from: https://data.stats.gov.cn/english/

54. van Dussen L, Biegstraaten M, Hollak CEM, Dijkgraaf MGW. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis. 2014;9:51.

55. Statistical Bulletin of China’s Health Development (2018) [Internet]. [cited 2020 Nov 18]. http://www.nhc.gov.cn/guixuaxxx/s11074/201905/9bd852727c3f46049d5edacce25f9b0d.shtml

56. Ci X, Yang H, Genchev GZ, Lu H, Yu G. Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai. Orphanet J Rare Dis. 2019;14:233.

57. WHO | Negotiating prices of drugs for rare diseases [Internet]. WHO. [cited 2020 Dec 4]. http://www.who.int/medicines/publications/essentialmedicines/2018/09/04/WHO_EMC_2018_09_04.pdf

58. Huang R, Shao W. China Rare Disease Drug Accessibility Report [Internet]. 2017. Available from: https://www.who.int/bulletin/volumes/94/10/16-13519/en/

59. Huang R, Kang Q, Hu J, Kong F, Tang M, He J, et al. Accessibility of drugs for rare diseases in China: policies and current situation. Intractable Rare Dis Res. 2019;8:80–8.

60. Guan X, Zhang J, Man C, Ni B, Shi L. How far have we come? Challenges to orphan drug access in China, 2011–2017. J Pharm Sci. 2019;108:2199–205.

61. He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. Intract Rare Dis Res. 2018;7:145–7.

62. Cheng A, Xie Z. Challenges in orphan drug development and regulatory policy in China. Orphanet J Rare Dis. 2017;12:13.

63. Dong D, Wang Y. Challenges of rare diseases in China. Lancet. 2016;387:1906.

64. Guan X, Qi L, Liu L. Controversy in public hospital reforms in China. Lancet Global Health. 2016;4:e240.

65. Picavet E, Morel T, Cassiman D, Simonis S. Shining a light in the black box of value rarity? BMJ. 2005;331:1016–9.

66. Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of value rarity? BMJ. 2005;331:1016–9.

67. Lucas F. Improving market access to rare diseases in China. Value Health. 2016;19:A883.

68. Shi H, Huang L, Xu L. Point of Care. 2018;2:2399202618810121.

69. GPhA Report: Savings: $1 trillion over 10 years—generic drug savings in the US. J Pharmaceut Health Serv Res. 2012;3:229–36.
comprehensive health care? Farmeconomia Health Econ Therap Pathways. 2012;13:5–20.
71. Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res. 1999;8:263–8.
72. Gengchun C. Optimizing the terms of mental health check about adults in city of our country—study on the degree of social support. J Xi’an Inst Phys Educ; 18:99–101
73. Xianchen L, Maoqin T, Lei H, Aizhen W, HongXin W, Guifang Z, et al. Reliability and validity of the Pittsburgh sleep quality index. Chin J Psychiatry. 1996;29:103–7.
74. Yanfang P, Chaozeng S, Huiqian H, Bin W, Guang L. Survey of health-related quality of life in population of 6 Chinese cities. Basic Clin Med. 2011;31:636–41.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.